Selwyn Ho

Dr. Selwyn Ho has over 20 years of international experience across Europe, US, and Asia in executive and senior management positions in both privately held and publicly traded biotech and pharma companies with a focus on inflammation and immunology, with various responsibilities in the areas of Product Development, Medical Affairs, Strategic Marketing and Market Access, Business Development and Licensing as well as Corporate Strategy and Financing.

In July 2022, Dr. Ho joined Medigene as CEO from Connect Biopharma (NASDAQ: CNTB) where he held the position of Chief Business Officer and, amongst other responsibilities, jointly led the execution of the company initial public offering (IPO) which closed in March 2021.

He also serves as an Executive-In-Residence at New Rhein Healthcare Investors, a venture capital and growth stage fund focused on healthcare therapeutics and medical devices and is a Non-Executive Director for Immodulon Therapeutics Ltd., a clinical stage company developing novel therapies for cancer based on bacterial derived immunomodulators.

Dr. Ho received his medical degree (MB BS) and Bachelor of Science (BSc) in Pharmacology from Imperial College, University of London, UK, and post-graduate qualifications (Dip Pharm Med) in Pharmaceutical Medicine from the Faculty of Pharmaceutical Physicians, Royal College of Physicians, UK.